In addition, caspase-1-related circular RNA (CACR) was increased in both high-glucose-treated cardiomyocytes and serum from diabetic patients, and CACR, as a competing endogenous RNA, promoted caspase-1 expression by targeting miR-214-3p, thereby inducing cardiomyocyte scorching, and thus CACR may be a new therapeutic target for DCM [43]. The gene discussed is CASP1; the disease is familial dilated cardiomyopathy.